Health workers in the Democratic Republic of Congo now have the government's approval to commence clinical trials for four experimental Ebola treatments and collect data on them.

"Precious information about the effectiveness of the treatments obtained during the clinical trial will allow for the development of these treatments on a wider scale to save more lives," read the statement from the DR Congo Health ministry.

The four treatments include ZMapp, an intravenous treatment made by Mapp Biopharmaceutical which got a lot of good publicity during the West African Ebola Epidemic of 2013-2016; Remdesivir, made by Gilead Sciences; mAb114, which was developed by the US government; and Regeneron's REGN-EB3.

The drugs have already been administered to 151 patients and have showed good results, reducing the mortality rate from 80 percent without treatment to 37 with treatment.

The United Nations World Health Organization issued an External Situation Report last week which expressed confidence that the outbreak can be contained, despite be contained widespread militia violence in eastern Congo and community resistance to health workers.